产 NDM-35 的 ST167 对包括头孢地尔在内的β-内酰胺类高度耐药。
NDM-35-Producing ST167 Highly Resistant to β-Lactams Including Cefiderocol.
机构信息
Emerging Antibiotic Resistance, Medical and Molecular Microbiology, Department of Medicine, University of Fribourg, Fribourg, Switzerlandgrid.8534.a.
Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
出版信息
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122. doi: 10.1128/aac.00311-22. Epub 2022 Jul 11.
Abstract
A multidrug-resistant (carbapenems, aztreonam + avibactam, and cefiderocol) ST167 Escherichia coli clinical isolate recovered from a patient hospitalized in Switzerland produced NDM-35 showing ca. 10-fold increased hydrolytic activity toward cefiderocol compared to NDM-1. The isolate co-produced a CMY-type β-lactamase, exhibited a four amino-acid insertion in PBP3, and possessed a truncated iron transporter CirA protein. Our study identified an association of unrelated resistance mechanisms leading to resistance to virtually all β-lactams in a high-risk E. coli clone.
摘要
一株多药耐药（碳青霉烯类、阿维巴坦+氨曲南和头孢地尔）ST167 型大肠埃希菌临床分离株，从一名在瑞士住院的患者中分离得到，该分离株可产生 NDM-35，对头孢地尔的水解活性比 NDM-1 高约 10 倍。该分离株还共同产生了一种 CMY 型β-内酰胺酶，在 PBP3 中存在四个氨基酸插入，并且具有截短的铁转运蛋白 CirA 蛋白。我们的研究发现，一种无关联的耐药机制与一种高风险大肠埃希菌克隆对几乎所有β-内酰胺类药物的耐药性有关。
相似文献
1
NDM-35-Producing ST167 Highly Resistant to β-Lactams Including Cefiderocol.
Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0031122. doi: 10.1128/aac.00311-22. Epub 2022 Jul 11.
2
Occurrence of High Levels of Cefiderocol Resistance in Carbapenem-Resistant Escherichia coli before Its Approval in China: a Report from China CRE-Network.
Microbiol Spectr. 2022 Jun 29;10(3):e0267021. doi: 10.1128/spectrum.02670-21. Epub 2022 Apr 28.
3
When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant in Canada.
Microbiol Spectr. 2024 May 2;12(5):e0322323. doi: 10.1128/spectrum.03223-23. Epub 2024 Mar 25.
4
NDM-8 metallo-β-lactamase in a multidrug-resistant Escherichia coli strain isolated in Nepal.
Antimicrob Agents Chemother. 2013 May;57(5):2394-6. doi: 10.1128/AAC.02553-12. Epub 2013 Mar 4.
5
Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-β-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.
Clin Infect Dis. 2024 Jun 14;78(6):1425-1428. doi: 10.1093/cid/ciad759.
6
An NDM-Producing Clinical Isolate Exhibiting Resistance to Cefiderocol and the Combination of Ceftazidime-Avibactam and Aztreonam: Another Step Toward Pan-β-Lactam Resistance.
Open Forum Infect Dis. 2023 May 17;10(7):ofad276. doi: 10.1093/ofid/ofad276. eCollection 2023 Jul.
7
The Growing Threat of NDM-Producing Escherichia coli With Penicillin-Binding Protein 3 Mutations in the United States-Is There a Potential Role for Durlobactam?
Clin Infect Dis. 2024 Oct 15;79(4):834-837. doi: 10.1093/cid/ciae229.
8
Biochemical analysis of metallo-β-lactamase NDM-3 from a multidrug-resistant Escherichia coli strain isolated in Japan.
Antimicrob Agents Chemother. 2014 Jun;58(6):3538-40. doi: 10.1128/AAC.02793-13. Epub 2014 Mar 31.
9
Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China.
Microbiol Spectr. 2022 Apr 27;10(2):e0008422. doi: 10.1128/spectrum.00084-22. Epub 2022 Mar 24.
10
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.
Clin Infect Dis. 2022 Aug 24;75(1):47-54. doi: 10.1093/cid/ciab888.
引用本文的文献
1
Evaluating Antimicrobial Susceptibility Testing Methods for Cefiderocol: A Review and Expert Opinion on Current Practices and Future Directions.
Antibiotics (Basel). 2025 Jul 28;14(8):760. doi: 10.3390/antibiotics14080760.
2
Cefiderocol "under siege"? Understanding the rise of NDM-mediated resistance to novel agents.
Chem Sci. 2025 Jun 3. doi: 10.1039/d5sc02122g.
3
Combined resistance mechanisms leading to high-level of cefiderocol resistance among NDM-like producing E. coli ST167 clinical isolates.
Eur J Clin Microbiol Infect Dis. 2025 May 27. doi: 10.1007/s10096-025-05166-w.
4
In vitro activity and resistance mechanisms of novel antimicrobial agents against metallo-β-lactamase producers.
Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1041-1068. doi: 10.1007/s10096-025-05080-1. Epub 2025 Mar 10.
5
Emergence of Carbapenem-Resistant Uropathogenic (ST405 and ST167) Strains Carrying , and Diverse Virulence Factors in Hospitalized Patients.
Pathogens. 2024 Nov 5;13(11):964. doi: 10.3390/pathogens13110964.
6
The Challenge of Treating Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria: A Narrative Review.
Drugs. 2024 Dec;84(12):1519-1539. doi: 10.1007/s40265-024-02102-8. Epub 2024 Oct 28.
7
Emergence of high-level aztreonam-avibactam and cefiderocol resistance following treatment of an NDM-producing bloodstream isolate exhibiting reduced susceptibility to both agents at baseline.
JAC Antimicrob Resist. 2024 Sep 5;6(5):dlae141. doi: 10.1093/jacamr/dlae141. eCollection 2024 Oct.
8
Characterizing carbapenemase-producing isolates from Spain: high genetic heterogeneity and wide geographical spread.
Front Cell Infect Microbiol. 2024 May 16;14:1390966. doi: 10.3389/fcimb.2024.1390966. eCollection 2024.
9
When the Trojan horse is unable to reach inside the city: investigation of the mechanism of resistance behind the first reported cefiderocol-resistant in Canada.
Microbiol Spectr. 2024 May 2;12(5):e0322323. doi: 10.1128/spectrum.03223-23. Epub 2024 Mar 25.
10
Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of strains producing broad-spectrum β-lactamases.
Antimicrob Agents Chemother. 2024 Apr 3;68(4):e0154823. doi: 10.1128/aac.01548-23. Epub 2024 Feb 28.
本文引用的文献
1
Impact of Acquired Broad-Spectrum β-Lactamases on Susceptibility to Cefiderocol and Newly Developed β-Lactam/β-Lactamase Inhibitor Combinations in Escherichia coli and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0003922. doi: 10.1128/aac.00039-22. Epub 2022 Mar 22.
2
New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0201121. doi: 10.1128/AAC.02011-21. Epub 2021 Dec 6.
3
Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA.
Microbiol Spectr. 2021 Dec 22;9(3):e0177921. doi: 10.1128/Spectrum.01779-21. Epub 2021 Nov 10.
4
Progressive Development of Cefiderocol Resistance in Escherichia coli During Therapy is Associated With an Increase in blaNDM-5 Copy Number and Gene Expression.
Clin Infect Dis. 2022 Aug 24;75(1):47-54. doi: 10.1093/cid/ciab888.
5
New Delhi Metallo-β-Lactamase-Producing Enterobacterales Bacteria, Switzerland, 2019-2020.
Emerg Infect Dis. 2021 Oct;27(10):2628-2637. doi: 10.3201/eid2710.211265.
6
Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.
Antimicrob Agents Chemother. 2021 Sep 17;65(10):e0087721. doi: 10.1128/AAC.00877-21. Epub 2021 Jul 12.
7
Molecular epidemiology of NDM-5-producing Escherichia coli high-risk clones identified in two Italian hospitals in 2017-2019.
Diagn Microbiol Infect Dis. 2021 Aug;100(4):115399. doi: 10.1016/j.diagmicrobio.2021.115399. Epub 2021 Apr 20.
8
Cross-Border Emergence of Escherichia coli Producing the Carbapenemase NDM-5 in Switzerland and Germany.
J Clin Microbiol. 2021 Feb 18;59(3). doi: 10.1128/JCM.02238-20.
9
New β-Lactam-β-Lactamase Inhibitor Combinations.
Clin Microbiol Rev. 2020 Nov 11;34(1). doi: 10.1128/CMR.00115-20. Print 2020 Dec 16.
10
Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates.
Antimicrob Agents Chemother. 2020 Nov 17;64(12). doi: 10.1128/AAC.01659-20.
Zotero 插件